Oncology

Matthew Warrick, PharmD, BCPS, BCOP, discusses mechanisms, safety nuances, and practical considerations shaping bispecific antibody use in lymphoma care.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

Key risks, overlooked toxicities, and real-world monitoring strategies for bispecific T-cell engagers.

Oncology pharmacist Emma Jones, PharmD, BCOP, outlines how clinicians can recognize and manage these complex cases.

A dual-center retrospective study compares 2 fludarabine washout strategies to assess their impact on neutrophil engraftment, infections, growth factor use, and hospital length of stay.

The indication is for patients who have received 1 to 3 prior systemic treatment regimens, of which at least 1 includes bevacizumab.

Disha Patel, PharmD, discusses current data on G-CSF use during HiDAC consolidation for AML, addressing relapse concerns, infection risk, clinical decision-making, and why practice patterns remain divided across institutions.

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.

Tucatinib triplet regimen with trastuzumab and capecitabine boosts survival and cerebrospinal fluid control in HER2-positive breast cancer leptomeningeal metastasis.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Biosimilars lower biologic costs and widen access.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Evolving myeloma therapies and pharmacist-led care reshape outcomes, tackling resistance, toxicity, and personalized treatment sequencing.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

FDA approval expands the use of teclistamab plus daratumumab, which significantly improved survival in the MajesTEC-3 trial.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.